Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab
- DOI
- 10.1016/j.esmogo.2025.100191
- Published
- 2025-09
- Container
- ESMO Gastrointestinal Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmogo.2025.100191,
title = {Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab},
author = {M. Fakih and F. Ciardiello and G.W. Prager and E. Élez and E. Calleja and N. Caussé-Amellal and J. Taieb and E. Van Cutsem},
year = {2025},
journal = {ESMO Gastrointestinal Oncology},
doi = {10.1016/j.esmogo.2025.100191},
url = {https://doi.org/10.1016/j.esmogo.2025.100191}
}RIS
TY - JOUR TI - Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab AU - M. Fakih AU - F. Ciardiello AU - G.W. Prager AU - E. Élez AU - E. Calleja AU - N. Caussé-Amellal AU - J. Taieb AU - E. Van Cutsem PY - 2025 JO - ESMO Gastrointestinal Oncology DO - 10.1016/j.esmogo.2025.100191 UR - https://doi.org/10.1016/j.esmogo.2025.100191 ER -
APA
Fakih, M., Ciardiello, F., Prager, G., Élez, E., Calleja, E., Caussé-Amellal, N., Taieb, J., & Cutsem, E. V. (2025). Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab. ESMO Gastrointestinal Oncology. https://doi.org/10.1016/j.esmogo.2025.100191
Source records
- crossref · retrieved 2026-09-27T10:52:22.875Z